Navigation Links
Zafgen Announces New Weight Loss and Safety Data from Phase 2 Study of Beloranib in Obesity at Obesity Week 2013
Date:11/15/2013

were allowed to eat normally and were not counseled to change their diet or exercise habits.

Results from this study showed that after 12 weeks of treatment, subjects on 0.6 mg, 1.2 mg, or 2.4 mg of beloranib lost on average (+/- standard error of mean) -5.5 +/- 0.5 kg, -6.9 +/- 0.6 kg, and -10.9 +/- 1.1 kg, respectively vs. -0.4 +/- 0.4 kg for those on placebo (all p<0.0001 vs. placebo).  The study also showed that weight loss with beloranib was progressive and continuing at week 12, reduced sense of hunger, improved cardiometabolic risk markers, and was generally well-tolerated.  In addition to confirming the findings from previous studies that showed improvements in LDL-cholesterol, HDL-cholesterol and triglycerides, this study also demonstrated beloranib's effects to lower blood pressure.  Using 24-hour Ambulatory Blood Pressure Monitoring, clinically and statistically significant improvements in systolic blood pressure were observed for the 1.2 mg and 2.4 mg doses, showing reductions of 7.6 mmHg and 12.0 mmHg, respectively.

There were no serious adverse events (AEs) deemed to be related to the study drug and no clinically significant abnormal laboratory measures, vital signs, or electrocardiography (ECG) findings.  The most common adverse events with a higher incidence rate in those taking beloranib vs. placebo were nausea, diarrhea, headache, injection site bruising, and insomnia.  These adverse events were generally mild, transient and self-limiting in nature.

"These full Phase 2 results are an exciting prospect for the treatment of severely obese patients," said Louis Aronne, M.D., Clinical Professor of Medicine at Weill Cornell Medical College.1 "Beloranib continues to demonstrate a unique ability to deliver rapid and significant weight loss as well as meaningful improvements in key cardiometabolic risk markers.  Based on this supporting data, beloranib has the
'/>"/>

SOURCE Zafgen, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Zafgen Announces Initiation of Phase 2a Clinical Development with Beloranib in Obesity
2. Zafgen Secures $21 Million in Series D Financing
3. Precision Optics Corporation Announces $1 Million Order for Microprecision™ Based Endoscopes
4. Young Innovations, Inc. Announces Record Sales and EPS for the Quarter Ended March 31, 2012
5. JDRF Announces Research Collaboration with Dexcom, Inc. to Develop "Smart Transmitter" Technology to Accelerate Artificial Pancreas Studies
6. Misonix Announces New Distribution Agreement For Panama
7. University of Maryland BioPark Announces MedImmunes Dr. Bahija Jallal as Newest Member of Board of Directors for UM Health Sciences Research Park
8. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
9. Boston Scientific Announces CE Mark and European Launch of Emerge™ PTCA Dilatation Catheter
10. Soligenix Announces Further Progress with ThermoVax™ for Long-Term Vaccine ThermoStability
11. Masimo Announces New Low-Profile Infant and Neonatal Pulse Oximetry Sensors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... CITY, Calif. , July 24, 2014   ... specialty pharmaceutical company focused on the development and commercialization ... breakthrough pain, today confirmed the PDUFA date for Zalviso ... learned that a rumor circulated online stating the Food ... July 24, 2014 there has been no notification to ...
(Date:7/24/2014)... , and MARSEILLE, France , ... , Exclusive global license from University of Tokyo enables ... sequencing (NGS) gene panels, for blood cancers  ... test, indicate favorable prognosis for patients with bone marrow ... potential for developing companion diagnostics to guide treatment with ...
(Date:7/24/2014)... Amgen (NASDAQ: AMGN ) today announced ... Tuesday, July 29, 2014, after the close of the U.S. ... call with the investment community at 2 p.m. PT. Participating ... Bradway , chairman and chief executive officer, and other members ... the conference call will be simultaneously broadcast over the Internet ...
Breaking Medicine Technology:AcelRx Pharmaceuticals Confirms July 27, 2014 PDUFA Date for Zalviso 2QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 2QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 3QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 4QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 5Amgen Announces Webcast of 2014 Second Quarter Financial Results 2
(Date:7/25/2014)... July 25, 2014 Newyorktermlifeinsurance.org has ... life insurance plans and traditional policies. , The ... clients make between no medical exam life insurance plans ... types of life insurance plans to provide a simple ... life insurance plans can now be purchased online. Although ...
(Date:7/25/2014)... July 25, 2014 CarePoint Health is ... Edward Boylan, has joined our network, CarePoint Health Medical ... Hundreds of highly skilled and experienced physicians comprise CarePoint ... and practices in Hudson County, representing a wide range ... to provide the highest quality care to patients and ...
(Date:7/25/2014)... Rockville Centre, NY (PRWEB) July 25, 2014 ... national personal injury law firm with over 25 ... of harm stemming from dangerous prescription drugs, announces ... , to offer information to those who believe ... Xarelto. , The site offers valuable information ...
(Date:7/25/2014)... TX (PRWEB) July 25, 2014 ... Outlook to 2020” provides company shares and distribution ... and global corporate-level profiles of the key market ... to the Laryngoscopes market wherever available. , The ... market forecast models. Rsearcher uses epidemiology and capital ...
(Date:7/25/2014)... Although cervical cancers are declining in the United States ... are increasing, a new study indicates. HPV-related cancers ... and tonsils have increased over the past 35 years, ... Canadian researchers report. "The increases in the incidence ... anal cancer among younger women are disturbing, because there ...
Breaking Medicine News(10 mins):Health News:No Medical Exam Life Insurance and Traditional Plans - Newyorktermlifeinsurance.org Provides Quotes for All Types of Life Insurance 2Health News:Dr. Boylan Joins CarePoint Health Medical Group 2Health News:Rottenstein Law Group LLP Announces Launch of Xarelto Injury Website 2Health News:Canada Cystoscopes, Laryngoscopes & Ureteroscopes Market Forecast to 2020 Reports Available at MarketOptimizer.org 2Health News:Canada Cystoscopes, Laryngoscopes & Ureteroscopes Market Forecast to 2020 Reports Available at MarketOptimizer.org 3Health News:Canada Cystoscopes, Laryngoscopes & Ureteroscopes Market Forecast to 2020 Reports Available at MarketOptimizer.org 4Health News:Canada Cystoscopes, Laryngoscopes & Ureteroscopes Market Forecast to 2020 Reports Available at MarketOptimizer.org 5Health News:Anal, Throat Cancers on the Rise Among Young Adults, Study Finds 2
... In a study of 14 adults with histories of ... not appear// to have effects that indicate potential for ... report in the October issue of Archives of General ... to 15 percent of adults regularly experience chronic insomnia, ...
... the time, they are nothing but a cosmetic nuisance. ... dividing abnormally to form a deadly form of skin ... this year will be diagnosed with melanoma at some ... percent of all melanomas begin in a mole. They ...
... of Nutrition in its current issue (October) has published ... Cookies TM can not only lower cholesterol levels but ... This would substantially curtail the risk of cardiac disease. ... purposes taken from the common fleawort, proven to be ...
... Health and Clinical Excellence (Nice) has planned new guidelines ... (porous bones) are at higher risk of fractures. The ... fragile bones. ,Post menopausal women at any ... wants to execute guidelines according to which, only women ...
... World Action on Salt and Health has been launched today ... 2.5 million deaths a year.// ,194 medical experts in ... companies into reducing dietary salt intake to prevent high blood ... a World Health Organisation summit in Paris to discuss the ...
... research proposes that the drug used to treat wet age-related ... vision in some people. // ,Wet AMD is the ... can be regained to some extent in people with a ... drug Lucentis. ,The study was published in the ...
Cached Medicine News:Health News:New Sleep Medication not Effective for Treating Abuse or Cognitive Impairment 2Health News:New Sleep Medication not Effective for Treating Abuse or Cognitive Impairment 3Health News:Why Don’t All Moles Progress to Melanoma 2Health News:Why Don’t All Moles Progress to Melanoma 3Health News:Chocolate Chip Cookies to Keep Cholesterol at Bay 2Health News:Food Makers Pressurized to Reduce Salt 2Health News:Vision restoration with a drug for macular degeneration 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: